FDA Oncology Reviews Need Common “Best Practices” – Erbitux Follow-Up
Executive Summary
FDA's drug and biologic centers should institute common "best practices" for oncology reviews, the Energy & Commerce Committee told the agency in a June 27 follow-up to the Erbitux hearing
You may also be interested in...
Accelerated Approval, Arava, Factive Are Topics For Early 2003 Committees
FDA's accelerated approval policies for cancer agents, a review of GeneSoft's Factive, and a safety update for Aventis' rheumatoid arthritis drug Arava are among the topics for advisory committees in early 2003
Accelerated Approval, Arava, Factive Are Topics For Early 2003 Committees
FDA's accelerated approval policies for cancer agents, a review of GeneSoft's Factive, and a safety update for Aventis' rheumatoid arthritis drug Arava are among the topics for advisory committees in early 2003
CBER/CDER Merger Is One Topic Of Erbitux Discussions In House Cmte.
The House Energy & Commerce Committee investigation of the Erbitux review could re-energize proposals to combine FDA's drugs and biologics centers